Reverdia Starts World’s First Large-Scale Bio-Based Succinic Acid Plant

Reverdia has begun operations in Cassano Spinola, Italy, at a commercial-scale...
Reverdia has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium sustainable succinic acid.

Reverdia, a global producer of starch and starch-derivatives, has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium sustainable succinic acid. The plant, which has a capacity of about 10,000 tons per year, is unique in its kind, being the world's first dedicated large-scale plant for the production of succinic acid from renewable resources.

It is also the only commercial facility to benefit from experience gained using low-pH yeast technology on a demonstration plant scale; Reverdia, a joint venture between life sciences and materials sciences company DSM and Roquette Frères, regards this as essential to be able to promise further improvements in product quality.

Key applications for Biosuccinium include polybutylene succinate (PBS), polyester polyols for polyurethanes, coating and composite resins, phthalate-free plasticizers, and 1,4 butanediol. End products include footwear, packaging and paints.

"We feel honoured and proud to open this new era in the lives of Reverdia and Biosuccinium," says Will van den Tweel, Reverdia's General Manager. "The new phase will enable direct and indirect customers to start production of commercial scale volumes of materials and end products based on bio-based succinic acid. These will be the first Biosuccinium-based products to find operational use in industry and to show up on retail shelves."

Company

Reverdia

Urmonderbaan 20H
6167 RD Geleen

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read